PBAC's latest decision on Amifampridine: Recommended with restriction (2022). Considered for Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$95k/QALY
Range: $75k/QALY–$95k/QALY
Submissions
2
first 2021
Submissions
2
2021 → 2022
Eligible population
Adults and children aged 6 years and above with Lambert-Eaton myasthenic syndrome (LEMS), including both paraneoplastic LEMS (pLEMS) and autoimmune LEMS (aLEMS).
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
QoL
Key trials
DAPPER, DUKE
Comparator
placebo
Economic model
CUA
Budget impact
$10M
Submission history
Nov 2021: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Authority Required — ICER $95k/QALY